Civic Intelligence

Sentinel Node Oncology Foundation

990EZ • Fiscal year 2023 • EIN 20-0173930

Jan 01, 2023 to Dec 31, 2023 • Filed on May 24, 2024

Organization ProfileN/A
62 Richardson RoadNovato, CA 94949

(415) 506-0138

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

61st percentile

0.00x

Higher debt load relative to assets than 61% of similar nonprofits.

2023 filings • 501(c)3 • <$500k nonprofits • Source year 2023

Liabilities / Revenue

67th percentile

0.01x

Higher debt load relative to revenue than 67% of similar nonprofits.

2023 filings • 501(c)3 • <$500k nonprofits • Source year 2023

Net Margin

7th percentile

-77%

Higher net margin than 7% of similar nonprofits.

2023 filings • 501(c)3 • <$500k nonprofits • Source year 2023

Top Officer Pay

78th percentile

$0

Higher top officer pay than 78% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

2023 filings • 501(c)3 • <$500k nonprofits • Source year 2023

Asset Growth

27th percentile

-15%

Faster asset growth than 27% of similar nonprofits.

2023 filings • 501(c)3 • <$500k nonprofits • Annualized from 2022 to 2023

Revenue Growth

95th percentile

232%

Faster revenue growth than 95% of similar nonprofits.

2023 filings • 501(c)3 • <$500k nonprofits • Annualized from 2022 to 2023

Balance Sheet
Liabilities / Assets61st percentile

Assets

Down

$218,610

Down $39,398 (-15%) from 2022

Net Assets

Down

$218,110

Down $39,294 (-15%) from 2022

Liabilities

Down

$500

Down $104 (-17%) from 2022

Revenue And Expenses
Liabilities / Revenue67th percentileNet Margin7th percentile

Revenue

Up

$51,026

Up $35,671 (+232%) from 2022

Expenses

Up

$90,320

Up $73,449 (+435%) from 2022

Net Income

Down

-$39,294

Down $37,778 (-2492%) from 2022

Historical Trend

Balance Sheet Trend

Asset Growth27th percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$300K$200K$100K$0Assets 2008: $45,693Liabilities 2008: $02008Assets 2013: $147,929Liabilities 2013: $0Net Assets 2013: $147,9292013Assets 2014: $157,429Liabilities 2014: $0Net Assets 2014: $157,4292014Assets 2015: $185,476Liabilities 2015: $4,353Net Assets 2015: $181,1232015Assets 2016: $245,028Liabilities 2016: $6,804Net Assets 2016: $238,2242016Assets 2017: $209,710Liabilities 2017: $25Net Assets 2017: $209,6852017Assets 2018: $260,756Liabilities 2018: $6,383Net Assets 2018: $254,3732018Assets 2019: $281,173Liabilities 2019: $673Net Assets 2019: $280,5002019Assets 2020: $0Liabilities 2020: $0Net Assets 2020: $02020Assets 2021: $0Liabilities 2021: $0Net Assets 2021: $02021Assets 2022: $258,008Liabilities 2022: $604Net Assets 2022: $257,4042022Assets 2023: $218,610Liabilities 2023: $500Net Assets 2023: $218,1102023Assets 2024: $196,494Liabilities 2024: $11,791Net Assets 2024: $184,7032024

Highlighted filing

2023

Assets$218,610
Liabilities$500
Net Assets$218,110
Open 2023 Filing

Operations Trend

Revenue Growth95th percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$200K$150K$100K$50K$0-$50KRevenue 2008: $43,975Expenses 2008: $26,517Net Income 2008: $17,4582008Revenue 2013: $132,427Expenses 2013: $69,728Net Income 2013: $62,6992013Revenue 2014: $5,446Expenses 2014: $11,075Net Income 2014: -$5,6292014Revenue 2015: $17,475Expenses 2015: $18,707Net Income 2015: -$1,2322015Revenue 2016: $152,112Expenses 2016: $74,440Net Income 2016: $77,6722016Revenue 2017: $145,216Expenses 2017: $132,106Net Income 2017: $13,1102017Revenue 2018: $53,299Expenses 2018: $15,705Net Income 2018: $37,5942018Revenue 2019: $147,646Expenses 2019: $148,632Net Income 2019: -$9862019Revenue 2020: $9,027Expenses 2020: $14,977Net Income 2020: -$5,9502020Revenue 2021: $13,074Expenses 2021: $18,336Net Income 2021: -$5,2622021Revenue 2022: $15,355Expenses 2022: $16,871Net Income 2022: -$1,5162022Revenue 2023: $51,026Expenses 2023: $90,320Net Income 2023: -$39,2942023Revenue 2024: $20,366Expenses 2024: $48,110Net Income 2024: -$27,7442024

Highlighted filing

2023

Revenue$51,026
Expenses$90,320
Net Income-$39,294
Open 2023 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2023 to Dec 31, 2023
Signed
May 24, 2024
Return Version
2023v5.0
Gross Receipts
$51,026
Mission and Program Overview

Mission

To Advance the care and treatment of patients with solid cancer, and to develop new preventative strategies, diagnosis and treatemnts.

Advance the care and treatment of patients with solid cancer, and develop new preventative strategies, diagnosis and treatments.

Program Services

DescriptionGrantsExpenses
The International Congress on Cancer Metastasis through the Lymphovascular System was first held in 2005, with numerous publications summarizing these biennial meetings. In 2022, we summarized these significant findings in our recently published book on Cancer Metastasis through the Lymphovascular System [1]. Cancer heterogeneity due to mutation [2, 3] and epigenetic changes [4] with association of formation of neoantigens [5, 6] is well known. Cancer progression relating to the cancer microenvironment and the mechanisms of cancer metastasis are under intense study. The 9th International Congress on Cancer Metastasis through the Lymphovascular System, being held between May 46, 2019, in San Francisco addressed the molecular mechanisms of cancer metastasis from the cancer microenvironment to the sentinel lymph nodes in the majority of the cases, then to systemic sites in 20 review articles and 1 commentary. In this Special Issue: Molecular Mechanisms of Cancer Metastasis [7], Carolina Rodriquez-Tirado, and Soledad Sosa address the origins and behavior of disseminated tumor cells during minimal residual disease and dormancy. Jamie Magrill, Dan Moldoveanu, and Ian Watson attempt to map the spatial immune landscapes of the melanoma microenvironment. Likewise, Wendi Liu, Anusha Puri, Doris Fu, Lee Chan, Cassia Wang, Manolis Kellis, and Jiekun Yang dissect the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics. Further, Cassia Wang, Lee Chen, Doris Fu, Wendi Liu, Anusha Puri, Manolis Kellis, and Jiekun Yang define the antigen-presenting cells in cancer immunity relating to the mediation of immune checkpoint blockade. Regarding the host immune system, Pamela Basto and Nathan Reticker-Flynn interrogate the role of lymph node metastasis in systemic immune surveillance. David Jackson describes the trafficking of immune cells and potentially that of cancer cells through the lymphatic system. Stanley Leong and Marlys Witte address the route of cancer metastasis through the lymphatic versus blood vessels. Circulating tumor cells can be detected by liquid biopsy of cancer. Daniel Smit, Svenja Schneegans, and Klaus Pantel summarize the clinical applications of circulating tumor cells in patients with solid tumors. As a commentary, Tetiana Bowley and Dario Marchetti have applied liquid biopsy to identify the RPL/RPS gene signature of melanoma circulating tumor cells to be associated with brain metastasis. Regarding resistance to cancer treatment, Abhilash Deo, Jonathan Sleeman, and Yuval Shaked show that the development of resistance to cancer treatment may result in recurrence and metastasis. Using the model of bromodomaininhibition, Imran Khan and Mohammed Kashani-Sabet demonstrate that such inhibition may overcome treatment resistance in melanoma. As sentinel lymph node biopsy has become a significant staging procedure to define the status of the regional lymph nodes, especially in melanoma and breast cancer, several papers are devoted to the biological and clinical significance of sentinel lymph nodes. David Nathanson and Ian Wood deliver the Donald L Morton Memorial Lecture from a personal perspective. Jonathan Zager and David Hyams describe the potential utility of 31 gene analyses of melanoma to help guide treatment and surveillance of melanoma. Mark Faries emphasizes the critical role of melanoma sentinel lymph nodes for optimal treatment. In addition, Stanley Leong and Marlys Witte, in the paper mentioned above, re-introduce the concept of the development of a pre-metastatic niche in the sentinel lymph nodes by cytokines released by primary cancer so that the sentinel lymph nodes become pre-conditioned to accept cancer cells to grow and proliferate. Theresa Schwartz summarizes the role of regional lymph nodes in breast cancer and specifies the need for sentinel lymph node biopsy to stage the axilla for breast cancer. In the Henry Ford Health Symposium: Molecular Mechanisms of Breast Cancer Metastasis organized by David Nathanson, several submitted contributions include: (1) Multifaceted roles of lymphatic endothelial cells by Lothar Dieterich and Emma Reynaud; (2) The evolving cancer niche interaction during bone colonization by Xian Zhang and Yi-Hsuan Wu; (3) Anatomic and molecular characteristics associated with breast cancer metastasis by Dhananjay Chitale; and (4) Can we cure metastatic breast cancer? by Lajos Pusztai and Alejandro Rios-Hoyo. The section on Novel Frontiers in the Treatment of Metastatic Melanoma includes the following papers: (1) Neo-adjuvant therapy for advanced metastatic melanoma nodal disease by Sharon Cimarron and Giorgos Karakousis; (2) Updates on intralesional monotherapy and combination therapy for in-transit metastases from metastatic melanoma by Danielle DePalo, Matthew Perez, Anne Hulbers, Roger Bagge and Jonathan Zager; and (3) Current status on regional perfusions for in-transit lymphatic metastasis of the limb and uveal melanoma metastatic to the liver by Anne Huibers, Danielle DePalo, Matthew Perez, Jonathan Zager and Roger Bagge. The paper on Immune Responses against Cancer by Stanley Leong describes the background of immune interac-tion with cancer and the diversity of T cell repertoire against cancer. Kevin Kim summarizes the personalized therapy in oncology: melanoma as a model for the paradigm of molecular-targeted treatment approaches. Jessica Xing and Dino Stea delve into the molecular mechanisms of sensitivity and resistance to radiotherapy. Finally, Michael Bernas, Sara Al-Ghadban, Saskia Thiadens, Karen Ashforth, Walter Lin, Bauback Safa, Rudolf Buntic, Michael Paukshto, Alexandra Rovnaya, and Margaret McNeely describe the etiology and treatment of cancer-related secondary lymphedema, which is associated with cancer treatment including surgery and radiation therapy. The above-described manuscripts have been separately published by Clinical and Experimental Metastasis and indexed in Pubmed. The entire set of these publications based on the plenary presentations of the 9th International Congress on Cancer Metastasis through the Lymphovascular System held between May 46, 2019, in San Francisco (www.cancermetastasis.org) have been compiled into this Special Issue in print format as Cancer Metastasis through the Lymphovascular System: Molecular Mechanisms of Metastasis to be published by Clinical and Experimental Metastasis of Springer Nature. We greatly appreciate the excellent presentations of our speakers, and more so, they have graciously responded to our request to summarize their presentations in review articles or a commentary to be published in this Special Issue. We are grateful to the sponsors and exhibitors who have made this Congress successful. They are acknowledged on our website (www.cancermetastasis.org). We are indebted to the Editorial Board of the Clinical and Experimental Metastasis for allowing and helping us to publish the 9th International Congress on Cancer Metastasis presentations in this Special Issue. We plan to launch the next 10th International Congress on Cancer Metastasis through the Lymphovascular System in the Fall of 2025 in San Francisco.-$90,321
Compensation and Service Providers
Top Officer Pay78th percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
Stanley P LeongPresident & CEO-$0--
Barbara A PockajSecretary-$0--
Jonathan S ZagerVice President-$0--
Richard WhiteDirector-$0--
Lyall FahdenDirector-$0--
Richard HongDirector-$0--
Larry LevyDirector-$0--
Eric MogensenDirector-$0--
Melissa SitterDirector-$0--
Diane TillmanDirector-$0--
Filing and Contact Details

Filer

Filer Name
Sentinel Node Oncology Foundation
EIN
20-0173930
Phone
4155060138
Address
62 Richardson Road, Novato, CA 94949

Signing Officer

Name
Stanley P Leong
Title
President
Signed
2024-05-24
Discuss with paid preparer
Yes

Preparer

Firm
Richard K Chinlund CPA
Address
1299 Fourth Street Suite 506, San Rafael, CA 94901
Preparer
Richard K Chinlund CPA
Phone
4155263686
Supplemental Narrative

Additional Explanations

Other Revenue.1

“Security Market Fluctuation $3101”

Other Expenses.1005

“Travel $655”

Other Expenses.1007

“Conferences, Conventions, and Meetings $32261”

Other Expenses.1

“Event Planning $17500”

Other Expenses.2

“Information Technology $10218”

Other Expenses.3

“Symposium Operations $1576”

Other Expenses.4

“Food & Beverage $636”

Other Expenses.5

“Awards/Trophy $500”

Other Expenses.6

“Website Hosting $500”

Other Expenses.7

“Business Expenses $268”

Other Expenses.8

“Bank Fees $191”

Other Expenses.9

“Computer & Internet $100”

Total Liabilities.1001

“Accounts Payable and Accrued Expenses - Beginning $604 Accounts Payable and Accrued Expenses - Ending $500”

Raw XML Appendix207 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/BooksInCareOfDetail/PersonNm0Stanley P Leong
IRS990EZ/BooksInCareOfDetail/PhoneNum04155060138
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt062 Richardson Road
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0Novato
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0CA
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd094949
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt0258008
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt0218610
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/ContributionsGiftsGrantsEtcAmt07229
IRS990EZ/CostOfGoodsSoldAmt00
IRS990EZ/CostOrOtherBasisExpenseSaleAmt00
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt0-39294
IRS990EZ/FeesAndOtherPymtToIndCntrctAmt03771
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt0258008
IRS990EZ/Form990TotalAssetsGrp/EOYAmt0218610
IRS990EZ/FundraisingGrossIncomeAmt00
IRS990EZ/GrantsAndSimilarAmountsPaidAmt07000
IRS990EZ/GrossReceiptsAmt051026
IRS990EZ/InfoInScheduleOPartIIInd0X
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/InvestmentIncomeAmt03884
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingCashInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt0257404
IRS990EZ/NetAssetsOrFundBalancesEOYAmt0218110
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt0257404
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt0218110
IRS990EZ/OccupancyRentUtltsAndMaintAmt015144
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt60
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt70
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt80
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt90
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt60
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt70
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt80
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt90
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0Stanley P Leong
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1Barbara A Pockaj
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2Jonathan S Zager
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3Richard White
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm4Lyall Fahden
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm5Richard Hong
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm6Larry Levy
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm7Eric Mogensen
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm8Melissa Sitter
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm9Diane Tillman
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0President & CEO
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1Secretary
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2Vice President
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt4Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt5Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt6Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt7Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt8Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt9Director
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherExpensesTotalAmt064405
IRS990EZ/OtherRevenueTotalAmt03101
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0Advance the care and treatment of patients with solid cancer, and develop new preventative strategies, diagnosis and treatments.
IRS990EZ/ProgramServiceRevenueAmt036812
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0The International Congress on Cancer Metastasis through the Lymphovascular System was first held in 2005, with numerous publications summarizing these biennial meetings. In 2022, we summarized these significant findings in our recently published book on Cancer Metastasis through the Lymphovascular System [1]. Cancer heterogeneity due to mutation [2, 3] and epigenetic changes [4] with association of formation of neoantigens [5, 6] is well known. Cancer progression relating to the cancer microenvironment and the mechanisms of cancer metastasis are under intense study. The 9th International Congress on Cancer Metastasis through the Lymphovascular System, being held between May 46, 2019, in San Francisco addressed the molecular mechanisms of cancer metastasis from the cancer microenvironment to the sentinel lymph nodes in the majority of the cases, then to systemic sites in 20 review articles and 1 commentary. In this Special Issue: Molecular Mechanisms of Cancer Metastasis [7], Carolina Rodriquez-Tirado, and Soledad Sosa address the origins and behavior of disseminated tumor cells during minimal residual disease and dormancy. Jamie Magrill, Dan Moldoveanu, and Ian Watson attempt to map the spatial immune landscapes of the melanoma microenvironment. Likewise, Wendi Liu, Anusha Puri, Doris Fu, Lee Chan, Cassia Wang, Manolis Kellis, and Jiekun Yang dissect the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics. Further, Cassia Wang, Lee Chen, Doris Fu, Wendi Liu, Anusha Puri, Manolis Kellis, and Jiekun Yang define the antigen-presenting cells in cancer immunity relating to the mediation of immune checkpoint blockade. Regarding the host immune system, Pamela Basto and Nathan Reticker-Flynn interrogate the role of lymph node metastasis in systemic immune surveillance. David Jackson describes the trafficking of immune cells and potentially that of cancer cells through the lymphatic system. Stanley Leong and Marlys Witte address the route of cancer metastasis through the lymphatic versus blood vessels. Circulating tumor cells can be detected by liquid biopsy of cancer. Daniel Smit, Svenja Schneegans, and Klaus Pantel summarize the clinical applications of circulating tumor cells in patients with solid tumors. As a commentary, Tetiana Bowley and Dario Marchetti have applied liquid biopsy to identify the RPL/RPS gene signature of melanoma circulating tumor cells to be associated with brain metastasis. Regarding resistance to cancer treatment, Abhilash Deo, Jonathan Sleeman, and Yuval Shaked show that the development of resistance to cancer treatment may result in recurrence and metastasis. Using the model of bromodomaininhibition, Imran Khan and Mohammed Kashani-Sabet demonstrate that such inhibition may overcome treatment resistance in melanoma. As sentinel lymph node biopsy has become a significant staging procedure to define the status of the regional lymph nodes, especially in melanoma and breast cancer, several papers are devoted to the biological and clinical significance of sentinel lymph nodes. David Nathanson and Ian Wood deliver the Donald L Morton Memorial Lecture from a personal perspective. Jonathan Zager and David Hyams describe the potential utility of 31 gene analyses of melanoma to help guide treatment and surveillance of melanoma. Mark Faries emphasizes the critical role of melanoma sentinel lymph nodes for optimal treatment. In addition, Stanley Leong and Marlys Witte, in the paper mentioned above, re-introduce the concept of the development of a pre-metastatic niche in the sentinel lymph nodes by cytokines released by primary cancer so that the sentinel lymph nodes become pre-conditioned to accept cancer cells to grow and proliferate. Theresa Schwartz summarizes the role of regional lymph nodes in breast cancer and specifies the need for sentinel lymph node biopsy to stage the axilla for breast cancer. In the Henry Ford Health Symposium: Molecular Mechanisms o
IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt090321
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/ScheduleBNotRequiredInd0X
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SpecialEventsDirectExpensesAmt00
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/SumOfTotalLiabilitiesGrp/BOYAmt0604
IRS990EZ/SumOfTotalLiabilitiesGrp/EOYAmt0500
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TaxImposedOnOrganizationMgrAmt00
IRS990EZ/TaxImposedUnderIRC4911Amt00
IRS990EZ/TaxImposedUnderIRC4912Amt00
IRS990EZ/TaxImposedUnderIRC4955Amt00
IRS990EZ/TaxReimbursedByOrganizationAmt00
IRS990EZ/TotalExpensesAmt090320
IRS990EZ/TotalProgramServiceExpensesAmt090321
IRS990EZ/TotalRevenueAmt051026
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0N/A
IRS990ScheduleA/AmountsRcvdDsqlfyPersonGrp/TotalAmt00
IRS990ScheduleA/First5Years509Ind0X
IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearAmt07229
IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearMinus1YearAmt012125
IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearMinus2YearsAmt01250
IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearMinus3YearsAmt08386
IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/TotalAmt028990
IRS990ScheduleA/GovtFurnSrvcFcltsVl509Grp/TotalAmt00
IRS990ScheduleA/GrossInvestmentIncome509Grp/CurrentTaxYearAmt03884
IRS990ScheduleA/GrossInvestmentIncome509Grp/CurrentTaxYearMinus1YearAmt03230
IRS990ScheduleA/GrossInvestmentIncome509Grp/TotalAmt07114
IRS990ScheduleA/GrossReceiptsAdmissionsGrp/TotalAmt00
IRS990ScheduleA/GrossReceiptsNonUnrltBusGrp/TotalAmt00
IRS990ScheduleA/InvestmentIncomeAndUBTIGrp/CurrentTaxYearAmt03884
IRS990ScheduleA/InvestmentIncomeAndUBTIGrp/CurrentTaxYearMinus1YearAmt03230
IRS990ScheduleA/InvestmentIncomeAndUBTIGrp/TotalAmt07114
IRS990ScheduleA/InvestmentIncomeCYPct00.00000
IRS990ScheduleA/NetIncomeFromOtherUBIGrp/TotalAmt00
IRS990ScheduleA/OtherIncome509Grp/CurrentTaxYearAmt039913
IRS990ScheduleA/OtherIncome509Grp/TotalAmt039913
IRS990ScheduleA/Post1975UBTIGrp/TotalAmt00
IRS990ScheduleA/PubliclySupportedOrg509a2Ind0X
IRS990ScheduleA/PublicSupportCY509Pct00.00000
IRS990ScheduleA/PublicSupportTotal509Amt028990
IRS990ScheduleA/SubstantialContributorsAmtGrp/TotalAmt00
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft509Grp/TotalAmt00
IRS990ScheduleA/Total509Grp/CurrentTaxYearAmt07229
IRS990ScheduleA/Total509Grp/CurrentTaxYearMinus1YearAmt012125
IRS990ScheduleA/Total509Grp/CurrentTaxYearMinus2YearsAmt01250
IRS990ScheduleA/Total509Grp/CurrentTaxYearMinus3YearsAmt08386
IRS990ScheduleA/Total509Grp/TotalAmt028990
IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearAmt051026
IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearMinus1YearAmt015355
IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearMinus2YearsAmt01250
IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearMinus3YearsAmt08386
IRS990ScheduleA/TotalSupportCalendarYearGrp/TotalAmt076017
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0Security Market Fluctuation $3101
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1Travel $655
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2Conferences, Conventions, and Meetings $32261
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3Event Planning $17500
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt4Information Technology $10218
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt5Symposium Operations $1576
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt6Food & Beverage $636
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt7Awards/Trophy $500
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt8Website Hosting $500
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt9Business Expenses $268
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt10Bank Fees $191
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt11Computer & Internet $100
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt12Accounts Payable and Accrued Expenses - Beginning $604 Accounts Payable and Accrued Expenses - Ending $500
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Other Revenue.1
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1Other Expenses.1005
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2Other Expenses.1007
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3Other Expenses.1
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc4Other Expenses.2
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc5Other Expenses.3
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc6Other Expenses.4
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc7Other Expenses.5
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc8Other Expenses.6
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc9Other Expenses.7
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc10Other Expenses.8
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc11Other Expenses.9
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc12Total Liabilities.1001
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/AuthenticationAssuranceLevelCd0AAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/FederatedAssuranceLevelCd0FAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/IdentityAssuranceLevelCd0IAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/TrustedCustomerCd02
ReturnHeader/BuildTS02023-04-26 12:10:37Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0Stanley P Leong
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0President
ReturnHeader/BusinessOfficerGrp/SignatureDt02024-05-24
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0Sentinel Node Oncology Foundation
ReturnHeader/Filer/BusinessNameControlTxt0SENT
ReturnHeader/Filer/EIN0200173930
ReturnHeader/Filer/PhoneNum04155060138
ReturnHeader/Filer/USAddress/AddressLine1Txt062 Richardson Road
ReturnHeader/Filer/USAddress/CityNm0Novato
ReturnHeader/Filer/USAddress/StateAbbreviationCd0CA
ReturnHeader/Filer/USAddress/ZIPCd094949
ReturnHeader/IRSResponsiblePrtyInfoCurrInd0true
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0721532721
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0Richard K Chinlund CPA
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt01299 Fourth Street Suite 506
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0San Rafael
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0CA
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd094901
ReturnHeader/PreparerPersonGrp/PhoneNum04155263686
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0Richard K Chinlund CPA
ReturnHeader/PreparerPersonGrp/SelfEmployedInd0X
ReturnHeader/ReturnTs02024-05-24T12:15:32-07:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonFirstNm0Stanley P
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonLastNm0Leong
ReturnHeader/TaxPeriodBeginDt02023-01-01
ReturnHeader/TaxPeriodEndDt02023-12-31
ReturnHeader/TaxYr02023

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2023 • Form 990EZDetailed filing. Detailed filing data is available for this year.

Open filing
Assets
$218,610
Liabilities
$500
Net assets
$218,110
Revenue
$51,026
Expenses
$90,320
Net income
-$39,294
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Detailed filing. Detailed filing data is available for this year.$1.96$0.12$1.85$0.20$0.48$0.28
2023Detailed filing. Detailed filing data is available for this year.$2.19$0.01$2.18$0.51$0.90$0.39
2022Detailed filing. Detailed filing data is available for this year.$2.58$0.01$2.57$0.15$0.17$0.02
2021Detailed filing. Detailed filing data is available for this year.$0.00$0.00$0.00$0.13$0.18$0.05
2020Detailed filing. Detailed filing data is available for this year.$0.00$0.00$0.00$0.09$0.15$0.06
2019Detailed filing. Detailed filing data is available for this year.$2.81$0.01$2.81$1.48$1.49$0.01
2018Detailed filing. Detailed filing data is available for this year.$2.61$0.06$2.54$0.53$0.16$0.38
2017Detailed filing. Detailed filing data is available for this year.$2.10$0.00$2.10$1.45$1.32$0.13
2016Detailed filing. Detailed filing data is available for this year.$2.45$0.07$2.38$1.52$0.74$0.78
2015Detailed filing. Detailed filing data is available for this year.$1.85$0.04$1.81$0.17$0.19$0.01
2014Detailed filing. Detailed filing data is available for this year.$1.57$0.00$1.57$0.05$0.11$0.06
2013Detailed filing. Detailed filing data is available for this year.$1.48$0.00$1.48$1.32$0.70$0.63
2008Summary only. Only limited summary data is available for this year.$0.46$0.00$0.44$0.27$0.17